Definitive Healthcare (NASDAQ:DH) Rating Lowered to Buy at Wall Street Zen

Definitive Healthcare (NASDAQ:DH) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

Other equities analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Definitive Healthcare in a report on Wednesday, October 8th. Canaccord Genuity Group reduced their price objective on Definitive Healthcare from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Monday, November 10th. Barclays decreased their target price on Definitive Healthcare from $3.00 to $2.75 and set an “underweight” rating for the company in a research report on Monday, December 8th. Morgan Stanley reiterated an “underperform” rating and set a $3.50 target price on shares of Definitive Healthcare in a report on Thursday, December 18th. Finally, William Blair upgraded Definitive Healthcare to a “strong-buy” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $3.94.

Definitive Healthcare Stock Up 0.4%

Shares of NASDAQ:DH opened at $2.63 on Friday. The stock has a 50-day simple moving average of $2.67 and a 200-day simple moving average of $3.44. The stock has a market capitalization of $371.78 million, a P/E ratio of -1.57 and a beta of 1.60. Definitive Healthcare has a 1 year low of $2.15 and a 1 year high of $5.68. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.60 and a current ratio of 1.60.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.06 by $0.01. Definitive Healthcare had a negative net margin of 77.88% and a positive return on equity of 3.30%. The firm had revenue of $60.05 million for the quarter, compared to analyst estimates of $59.51 million. Definitive Healthcare has set its FY 2025 guidance at 0.230-0.240 EPS and its Q4 2025 guidance at 0.050-0.060 EPS. Equities analysts forecast that Definitive Healthcare will post 0.16 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of DH. Raymond James Financial Inc. purchased a new stake in Definitive Healthcare during the 2nd quarter worth approximately $32,000. Farther Finance Advisors LLC acquired a new stake in shares of Definitive Healthcare during the second quarter worth approximately $33,000. Savant Capital LLC bought a new stake in shares of Definitive Healthcare in the second quarter worth $45,000. Los Angeles Capital Management LLC acquired a new stake in Definitive Healthcare in the second quarter valued at $51,000. Finally, Ariadne Wealth Management LP acquired a new stake in Definitive Healthcare in the third quarter valued at $54,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.

Definitive Healthcare Company Profile

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.